Fatima Cody Stanford1, Hellas Cena2,3, Ginevra Biino4, Olivia Umoren5, Monik Jimenez6, Marlene P Freeman5, Aladdin H Shadyab7, Robert A Wild8, Catherine R Womack9, Hailey R Banack10, JoAnn E Manson6,11. 1. Internal Medicine - Neuroendocrine Division and Pediatric Endocrinology, MGH Weight Center, Nutrition Obesity Research Center at Harvard, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 2. Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy. 3. Clinical Nutrition and Dietetics Service, Unit of Internal Medicine and Endocrinology, ICS Maugeri I.R.C.C.S, Pavia, Italy. 4. Institute of Molecular Genetics, National Research Council of Italy, Pavia, Italy. 5. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 6. Division of Women's Health and Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 7. Division of Epidemiology, Department of Family Medicine and Public Health, University of California, San Diego School of Medicine, La Jolla, CA. 8. Departments of Obstetrics and Gynecology, Biostatistics and Epidemiology, Family and Preventive Medicine, Oklahoma University Health Sciences Center, Oklahoma City, OK. 9. The University of Tennessee Health Science Center, Memphis, TN. 10. Department of Epidemiology and Environmental Health, The State University of New York at Buffalo, Buffalo, NY. 11. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
Abstract
OBJECTIVE: With the rise in obesity, there has been a concomitant increase in prescription medications associated with weight gain. The objective of this study is to quantify the magnitude of association between putative weight-promoting medications and 3-year weight change in a diverse cohort of postmenopausal women in the Women's Health Initiative (WHI). METHODS: This is a prospective observational cohort study, considering 40 sites in the WHI and a cohort of seventy six thousand two hundred fifty-two postmenopausal women aged 50-79 years, with weight measured at both baseline and 3 years, in the WHI-Observational Study. Body mass index (BMI) and waist circumference (WC) were measured at baseline and 3 years. An in-clinic medication inventory identified prescribed medications, including antidepressants, beta-blockers, insulin, and/or glucocorticosteroids. Generalized linear models evaluated if intermittent or persistent use of weight-promoting drugs was associated with increased BMI and WC during a 3-year follow up. RESULTS: Women with overweight or obesity at baseline were more likely to be taking antidepressants, beta-blockers, and/or insulin. Taking at least one putative weight-promoting medication was associated with a greater increase in BMI (0.37 vs 0.27 kg/m, P = 0.0045) and WC (1.10 cm vs 0.89 cm, P = 0.0077) over the course of 3 years compared to women not on these medications. Both BMI and WC increased with the number of weight-promoting drugs prescribed (P for trend per medication used < 0.00001 for both variables). Those who took either antidepressants or insulin, or a combination of antidepressants and beta-blockers, were most likely to have a significant increase in BMI compared to nonusers. CONCLUSIONS: Antidepressants, beta-blockers, and insulin were associated with weight gain in postmenopausal women. This information may help to inform clinical decision-making and efforts to mitigate medication-related weight gain. : Video Summary:http://links.lww.com/MENO/A617.
OBJECTIVE: With the rise in obesity, there has been a concomitant increase in prescription medications associated with weight gain. The objective of this study is to quantify the magnitude of association between putative weight-promoting medications and 3-year weight change in a diverse cohort of postmenopausal women in the Women's Health Initiative (WHI). METHODS: This is a prospective observational cohort study, considering 40 sites in the WHI and a cohort of seventy six thousand two hundred fifty-two postmenopausal women aged 50-79 years, with weight measured at both baseline and 3 years, in the WHI-Observational Study. Body mass index (BMI) and waist circumference (WC) were measured at baseline and 3 years. An in-clinic medication inventory identified prescribed medications, including antidepressants, beta-blockers, insulin, and/or glucocorticosteroids. Generalized linear models evaluated if intermittent or persistent use of weight-promoting drugs was associated with increased BMI and WC during a 3-year follow up. RESULTS: Women with overweight or obesity at baseline were more likely to be taking antidepressants, beta-blockers, and/or insulin. Taking at least one putative weight-promoting medication was associated with a greater increase in BMI (0.37 vs 0.27 kg/m, P = 0.0045) and WC (1.10 cm vs 0.89 cm, P = 0.0077) over the course of 3 years compared to women not on these medications. Both BMI and WC increased with the number of weight-promoting drugs prescribed (P for trend per medication used < 0.00001 for both variables). Those who took either antidepressants or insulin, or a combination of antidepressants and beta-blockers, were most likely to have a significant increase in BMI compared to nonusers. CONCLUSIONS: Antidepressants, beta-blockers, and insulin were associated with weight gain in postmenopausal women. This information may help to inform clinical decision-making and efforts to mitigate medication-related weight gain. : Video Summary:http://links.lww.com/MENO/A617.
Authors: Adrianne C Feldstein; Gregory A Nichols; David H Smith; A Gabriela Rosales; Nancy Perrin Journal: J Gen Intern Med Date: 2008-06-28 Impact factor: 5.128
Authors: Rhonda M Cooper-DeHoff; Sheron Wen; Amber L Beitelshees; Issam Zineh; John G Gums; Stephen T Turner; Yan Gong; Karen Hall; Vishal Parekh; Arlene B Chapman; Eric Boerwinkle; Julie A Johnson Journal: Hypertension Date: 2009-11-16 Impact factor: 10.190